Specialty Pharmacy

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.

A study reveals that axial psoriatic arthritis and ankylosing spondylitis with psoriasis are different diseases with different genetics, demographics, and disease expression.

Findings from a phase 3 study reinforced the safety and efficacy of rituximab (Rituxan, Genentech) as a treatment for patients with pemphigus vulgaris.

Top news of the day from across the health care landscape.

Jesse C. Dresser, Esq explains how DIR fees affect specialty pharmacists at the NASP Annual Meeting in Washington, DC.

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.

Top news of the day from across the health care landscape.

Annual Award Celebrates Electronic Health Records, Health Systems and Pharmacy Industry Leaders for Improving Patient Safety and Workflow Efficiency

A study looked at the incidence of thrombosis in patients being treated with ibrutinib for hematologic malignancies.

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

Oligodendrocyte progenitor cells were often ignored by scientists studying multiple sclerosis; however, new research shows that they are critical in its production.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how specialty pharmacists can show their value during the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

A supplemental New Drug Application (sNDA) was submitted to the FDA for ibrutinib (Imbruvica, AbbVie) in combination with rituximab for the first-line treatment of younger patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

With this approval, luspatercept-aamt (Reblozyl, Celgene) is the first FDA-approved erythroid maturation agent for anemia in beta thalassemia

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

A phase 3 study evaluated ixazomib (Ninlaro, Takeda) in the first-line maintenance therapy setting for patients with multiple myeloma who have not undergone autologous stem cell transplant.

The discovery is the first time a new subtype of HIV-1 has been identified since 2000.

Top news of the day from across the health care landscape.

Because cystic fibrosis transmembrane conductance regulator modulator therapies are new, researchers sought to understand patient adherence as well as potential challenges.

Top news of the week from Specialty Pharmacy Times.

Rituximab-abbs (Truxima, Teva and Celltrion), has been launched in the United States with a full oncology label for non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Top news of the day from across the health care landscape.